Oppenheimer reiterated coverage on Personalis with a new price target
$PSNL
Medical Specialities
Health Care
Oppenheimer reiterated coverage of Personalis with a rating of Outperform and set a new price target of $24.00 from $30.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2025 | $6.00 | Buy | Guggenheim |
| 3/17/2025 | $8.00 | Buy | Canaccord Genuity |
| 2/6/2023 | $8.00 | Hold → Buy | Needham |
| 2/6/2023 | Hold → Buy | Needham | |
| 2/25/2022 | $30.00 → $24.00 | Outperform | Oppenheimer |
| 2/25/2022 | $30.00 → $18.00 | Buy | Citigroup |
| 2/25/2022 | $50.00 → $38.00 | Buy | HC Wainwright & Co. |
| 1/7/2022 | $27.00 → $23.00 | Neutral → Buy | BofA Securities |